Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Aberger, S; Schuller, M; Mooslechner, AA; Klötzer, KA; Prietl, B; Pfeifer, V; Kirsch, AH; Rosenkranz, AR; Artinger, K; Eller, K.
T cell Activation Marker HLA-DR Reflects Tacrolimus-Associated Immunosuppressive Burden and BK Viremia Risk After Kidney Transplantation - An Observational Cohort Study.
Transpl Int. 2025; 38:14443
Doi: 10.3389/ti.2025.14443
[OPEN ACCESS]
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Aberger Simon Michael
- Artinger Katharina
- Co-authors Med Uni Graz
- Eller Kathrin
- Kirsch Alexander
- Klötzer Konstantin Adrian
- Mooslechner Agnes Anna
- Pfeifer Verena
- Prietl Barbara
- Rosenkranz Alexander
- Schuller Max
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Kidney transplantation (KT) is the current treatment of choice in patients with end-stage kidney disease. Immunosuppression is required to prevent acute rejection but is associated with a high incidence of adverse events. The immunosuppressive burden substantially differs between individuals, necessitating new immune monitoring strategies to achieve personalization of immunosuppression. To compare the evolution of T cell profiles in correlation with immunosuppression and clinical outcomes, 87 kidney transplant recipients were followed for 12 months after KT. Flow cytometry along with assessment of T cell activation markers and clinical data was performed before KT and during study visits 10 days, 2 months and 12 months after KT. Longitudinal T cell phenotyping revealed a significant decrease of T cell activation markers HLA-DR, FCRL3, and CD147 in CD4+ effector T cells after KT. The most pronounced reduction (75%) was found for the activation-proliferation marker HLA-DR, which persisted throughout the observational period. The decrease in HLA-DR expression reflected immunosuppressive burden through strong associations with tacrolimus trough-level exposure (coeff = -0.39, p < 0.01) and BK viremia incidence (coeff = -0.40, p < 0.01) in multivariable regression analysis. T cell activation marker HLA-DR emerges as a potential biomarker for tacrolimus-related immunosuppressive burden in association with BK viremia risk following KT.
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- Tacrolimus - adverse effects, therapeutic use
- Kidney Transplantation - adverse effects
- Male - administration & dosage
- Immunosuppressive Agents - adverse effects, therapeutic use
- Female - administration & dosage
- Middle Aged - administration & dosage
- HLA-DR Antigens - metabolism
- Viremia - administration & dosage
- Adult - administration & dosage
- BK Virus - administration & dosage
- Polyomavirus Infections - immunology
- Lymphocyte Activation - administration & dosage
- Biomarkers - metabolism
- T-Lymphocytes - immunology
- Aged - administration & dosage
- Tumor Virus Infections - immunology
- Cohort Studies - administration & dosage
- Kidney Failure, Chronic - surgery
- Graft Rejection - prevention & control